Literature DB >> 8656038

Analysis of the lipids of normal and Gaucher bone marrow.

S P Miller1, G C Zirzow, S H Doppelt, R O Brady, N W Barton.   

Abstract

Quantitative chemical shift magnetic resonance imaging (QCSI) is currently being utilized for measuring the extent of bone marrow involvement and its response to enzyme replacement therapy in patients with Gaucher's disease. Quantitation of the major lipid species in human bone marrow is required to accurately interpret QCSI data on bone marrow composition. The major lipid species in bone marrow specimens from normal individuals and from patients with type 1 Gaucher's disease were analyzed by thin-layer and high-pressure liquid chromatography. In normal marrow (N = 5), triglycerides were by far the most abundant lipid (278 +/- 70 mg/gm wet wt), with other non-polar lipids and phospholipids totaling less than 20 mg/gm wet weight. The concentration of glucocerebroside in normal marrow was 0.061 +/- 0.06 mg/gm wet weight. Gaucher marrow (N = 9) had dramatically lower triglyceride levels (51 +/- 53 mg/gm wet wt), and as expected, it had markedly elevated levels of glucocerebroside (7.1 +/- 3.4 mg/gm wet wt). The other major non-polar lipids and phospholipids were measured in selected specimens, but none were found that differed so profoundly between normal and Gaucher's disease. These data support a model of bone marrow alteration in Gaucher's disease in which triglyceride-rich adipocytes are progressively replaced by storage cells, leading to an overall reduction in total lipid content. This phenomenon provides an explanation for the changes in proton signal intensity observed in QCSI studies of Gaucher bone marrow.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8656038     DOI: 10.1016/s0022-2143(96)90183-3

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  7 in total

1.  Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease.

Authors:  U H Schueler; T Kolter; C R Kaneski; G C Zirzow; K Sandhoff; R O Brady
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

Review 2.  Clinically relevant therapeutic endpoints in type I Gaucher disease.

Authors:  C E Hollak; M Maas; J M Aerts
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

3.  Global Sensitivity Analysis of the Rodgers and Rowland Model for Prediction of Tissue: Plasma Partitioning Coefficients: Assessment of the Key Physiological and Physicochemical Factors That Determine Small-Molecule Tissue Distribution.

Authors:  Estelle Yau; Andrés Olivares-Morales; Michael Gertz; Neil Parrott; Adam S Darwich; Leon Aarons; Kayode Ogungbenro
Journal:  AAPS J       Date:  2020-02-03       Impact factor: 4.009

Review 4.  Evaluation of an imaging biomarker, Dixon quantitative chemical shift imaging, in Gaucher disease: lessons learned.

Authors:  L van Dussen; E M Akkerman; C E M Hollak; A J Nederveen; M Maas
Journal:  J Inherit Metab Dis       Date:  2014-06-13       Impact factor: 4.982

5.  Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.

Authors:  D Elstein; C Hollak; J M F G Aerts; S van Weely; M Maas; T M Cox; R H Lachmann; M Hrebicek; F M Platt; T D Butters; R A Dwek; A Zimran
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

Review 6.  Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring.

Authors:  T M Cox; J M F G Aerts; N Belmatoug; M D Cappellini; S vom Dahl; J Goldblatt; G A Grabowski; C E M Hollak; P Hwu; M Maas; A M Martins; P K Mistry; G M Pastores; A Tylki-Szymanska; J Yee; N Weinreb
Journal:  J Inherit Metab Dis       Date:  2008-05-23       Impact factor: 4.982

Review 7.  Gaucher Disease in Bone: From Pathophysiology to Practice.

Authors:  Derralynn Hughes; Peter Mikosch; Nadia Belmatoug; Francesca Carubbi; TimothyM Cox; Ozlem Goker-Alpan; Andreas Kindmark; PramodK Mistry; Ludger Poll; Neal Weinreb; Patrick Deegan
Journal:  J Bone Miner Res       Date:  2019-06-24       Impact factor: 6.741

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.